1312474-00-2

Upstream product

• 1312479-60-9 (2R)-4-[4-{4-[(6-methoxypyridin-3-yl)methoxy]phenyl}-2-oxopyridin-1(2H)-yl]-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1312479-58-5 5-[(4-bromophenoxy)methyl]-2-methoxypyridine 
• 1312479-59-6 2-methoxy-5-{[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl}pyridine 
• 1312478-57-1 (2R)-4-(4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)-N-(tetrahydro-2H-pyran-2-yloxy)butanamide 
• 1312478-59-3 (2R)-4-(4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoic acid 
• 1312478-58-2 benzyl (2R)-4-(4-iodo-2-oxopyridin-1(2H)-yl)-2-methyl-2-(methylsulfonyl)butanoate 
• 1312478-52-6 benzyl (2R)-4-bromo-2-methyl-2-(methylsulfonyl)butanoate 
• 1312478-51-5 benzyl (±)-4-bromo-2-methyl-2-(methylsulfonyl)butanoate 
• 858839-90-4 4-iodo-1,2-dihydropyridin-2-one 
• 22282-70-8 2-fluoro-4-iodopyridine 
• 26218-80-4 6-methoxy-nicotinic acid methyl ester 
• 58584-63-7 (6-methoxypyridin-3-yl)methanol 

Relevant academic research and scientific papers

N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. Formula (I).